Emerging Biotech Companies Embrace Veeva Basics for Accelerated Drug Development
In a significant move to streamline drug development, over 175 emerging biotech companies have adopted Veeva Basics, a suite of pre-configured applications designed to optimize operational processes. Made by Veeva Systems (NYSE: VEEV), these tools enable biotechs to introduce validated applications swiftly, transitioning smoothly from inception to market readiness.
Veeva Basics encompasses essential areas such as clinical, regulatory, quality, medical, and commercial operations, allowing companies to enhance innovation while reducing time, effort, and costs. With growing competition in the biotech landscape, utilizing such integrated solutions is no longer just advantageous but rather essential for success.
Bryan Ball, Chief Technology Operations Officer at Whitehawk Therapeutics, provides insight into the advantages brought by Veeva Basics. His company, focused on advancing research in antibody-drug conjugates for challenging cancers, highlights how their collaboration with Veeva has transformed their workflows. Previously reliant on cumbersome paper processes, the adoption of Veeva’s cutting-edge solutions enabled them to eliminate these inefficiencies without the need for extensive IT resources or complex customizations. This transition not only accelerated their operational speed but also improved compliance within their regulatory and quality assurance processes.
Furthermore, Veeva Basics allows biotech firms to adopt new operational strategies, particularly in handling regulatory submissions. The Veeva Submissions Publishing Basics offers a modern application for preparing submission documents. This empowers regulatory teams to manage interactions with health authorities internally, thus easing the path for companies preparing to submit their first applications to the FDA. The enhanced internal control and transparency help these firms achieve crucial regulatory milestones during their development cycles.
Darryl Clarke, Global Head of Regulatory Operations at Structure Therapeutics, emphasizes the strict quality control facilitated by Veeva Basics’ internal management of submission requests. The capability to process these applications internally has drastically shortened approval times with regulatory agencies, boosting overall efficiency. With globally supported modern applications that can be rapidly deployed and scaled as needed, biotech firms are equipped to handle future challenges more adeptly.
According to Jim Thai, Vice President at Veeva Basics, the innovation from biotech companies plays a pivotal role in shaping the industry. These enterprises require technologies that can match their pace and dynamic business environments. He expresses gratitude for collaborating with industry pioneers to build a community of Veeva Basics users dedicated to advancing drug development.
The applications powered by Veeva Basics are built on the robust Vault platform, enabling seamless adaptation of technology infrastructures as companies grow. For those wishing to learn more about Veeva Basics, the next opportunity is at the Veeva RD and Quality Summit, scheduled from October 20-21 in Boston, which caters exclusively to life sciences professionals.
In summary, Veeva Basics is becoming increasingly essential for emerging biotech companies striving for efficiency and innovation in drug development. By leveraging these specialized tools, they can not only streamline their operations but also enhance their competitiveness in a rapidly evolving sector. As the biotech landscape continues to evolve, tools like Veeva Basics will be pivotal in helping these companies achieve their goals and bring life-saving drugs to market more effectively.
Veeva Basics encompasses essential areas such as clinical, regulatory, quality, medical, and commercial operations, allowing companies to enhance innovation while reducing time, effort, and costs. With growing competition in the biotech landscape, utilizing such integrated solutions is no longer just advantageous but rather essential for success.
Bryan Ball, Chief Technology Operations Officer at Whitehawk Therapeutics, provides insight into the advantages brought by Veeva Basics. His company, focused on advancing research in antibody-drug conjugates for challenging cancers, highlights how their collaboration with Veeva has transformed their workflows. Previously reliant on cumbersome paper processes, the adoption of Veeva’s cutting-edge solutions enabled them to eliminate these inefficiencies without the need for extensive IT resources or complex customizations. This transition not only accelerated their operational speed but also improved compliance within their regulatory and quality assurance processes.
Furthermore, Veeva Basics allows biotech firms to adopt new operational strategies, particularly in handling regulatory submissions. The Veeva Submissions Publishing Basics offers a modern application for preparing submission documents. This empowers regulatory teams to manage interactions with health authorities internally, thus easing the path for companies preparing to submit their first applications to the FDA. The enhanced internal control and transparency help these firms achieve crucial regulatory milestones during their development cycles.
Darryl Clarke, Global Head of Regulatory Operations at Structure Therapeutics, emphasizes the strict quality control facilitated by Veeva Basics’ internal management of submission requests. The capability to process these applications internally has drastically shortened approval times with regulatory agencies, boosting overall efficiency. With globally supported modern applications that can be rapidly deployed and scaled as needed, biotech firms are equipped to handle future challenges more adeptly.
According to Jim Thai, Vice President at Veeva Basics, the innovation from biotech companies plays a pivotal role in shaping the industry. These enterprises require technologies that can match their pace and dynamic business environments. He expresses gratitude for collaborating with industry pioneers to build a community of Veeva Basics users dedicated to advancing drug development.
The applications powered by Veeva Basics are built on the robust Vault platform, enabling seamless adaptation of technology infrastructures as companies grow. For those wishing to learn more about Veeva Basics, the next opportunity is at the Veeva RD and Quality Summit, scheduled from October 20-21 in Boston, which caters exclusively to life sciences professionals.
In summary, Veeva Basics is becoming increasingly essential for emerging biotech companies striving for efficiency and innovation in drug development. By leveraging these specialized tools, they can not only streamline their operations but also enhance their competitiveness in a rapidly evolving sector. As the biotech landscape continues to evolve, tools like Veeva Basics will be pivotal in helping these companies achieve their goals and bring life-saving drugs to market more effectively.
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.